E

    ESPR (ESPR)

    Official site

    DRUG MANUFACTURERS - SPECIALTY & GENERIC

    $3.18
    +0.00 (+0.00%)

    Last updated: Jul 13, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(21/39)
    Avg Surprise
    +97.79%

    Upcoming Estimates

    Jun 30, 2026
    EPS Consensus$-0.07
    Range$-0.07 - $-0.07
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.01+90.4%
    60d ago$-0.07+0.0%
    30d ago$-0.07+0.0%
    7d ago$-0.07+0.0%
    Current$-0.07
    Revenue Consensus
    $77M
    Range$77M - $77M
    1 analysts
    Sep 30, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.04
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$0.01+116.8%
    60d ago$-0.04+0.0%
    30d ago$-0.04+0.0%
    7d ago$-0.04+0.0%
    Current$-0.04
    Revenue Consensus
    $86M
    Range$86M - $86M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.07---
    Sep 26EST
    		-$-0.04---
    Jun 26EST
    		-$-0.07---
    Mar 26
    		$-0.10$-0.04-150.00%Miss+52.4%
    Dec 25
    		$0.22$0.28-21.43%Miss+317.2%
    Sep 25
    		$-0.16$-0.08-100.00%Miss-6.7%
    Jun 25
    		$-0.02N/A+87.50%Beat+60.0%
    Mar 25
    		$-0.21$-0.15-40.00%Miss-161.8%
    Dec 24
    		$-0.10$-0.16+35.68%Beat+79.7%
    Sep 24
    		$-0.15$-0.17+11.76%Beat+59.5%
    Jun 24
    		$-0.05N/A+70.59%Beat+89.1%
    Mar 24
    		$0.34$-0.01+3500.00%Beat+143.0%
    Dec 23
    		$-0.50$-0.48-4.17%Miss+34.2%
    Sep 23
    		$-0.37$-0.42+11.90%Beat+54.3%
    Jun 23
    		$-0.46$-0.63+26.98%Beat+56.2%
    Mar 23
    		$-0.79$-0.66-19.70%Miss+15.1%
    Dec 22
    		$-0.76$-0.85+10.59%Beat+57.1%
    Sep 22
    		$-0.81$-0.93+12.90%Beat+69.1%
    Jun 22
    		$-1.05$-0.92-14.13%Miss+37.1%
    Mar 22
    		$-0.93$-1.04+10.58%Beat+73.4%
    Dec 21
    		$-1.77$-2.27+22.03%Beat+54.5%
    Sep 21
    		$-2.62$-2.80+6.43%Beat+14.7%
    Jun 21
    		$-1.67$-1.85+9.73%Beat-138.7%
    Mar 21
    		$-3.50$-2.72-28.68%Miss-23.2%
    Dec 20
    		$-3.89$-3.76-3.46%Miss-72.1%
    Sep 20
    		$-3.07$-3.57+14.01%Beat-21.8%
    Jun 20
    		$4.32$1.40+208.57%Beat+314.9%
    Mar 20
    		$-2.84$-3.30+13.94%Beat-192.5%
    Dec 19
    		$-2.26$-2.67+15.36%Beat-0.9%
    Sep 19
    		$-2.52$-1.92-31.25%Miss-35.5%
    Jun 19
    		$-2.01$-1.82-10.44%Miss-17.5%
    Mar 19
    		$3.07$0.74+314.86%Beat+277.5%
    Dec 18
    		$-2.24$-1.12-100.00%Miss-55.6%
    Sep 18
    		$-1.86$-1.64-13.41%Miss+0.0%
    Jun 18
    		$-1.71$-1.72+0.58%Beat+10.9%
    Mar 18
    		$-1.73$-1.59-8.80%Miss+3.9%
    Dec 17
    		$-1.44$-1.79+19.55%Beat-11.6%
    Sep 17
    		$-1.86$-1.77-5.08%Miss-141.6%
    Jun 17
    		$-1.92$-1.62-18.52%Miss-
    Mar 17
    		$-1.80$-1.46-23.29%Miss-
    Dec 16
    		$-1.29$-1.22-5.74%Miss-
    Sep 16
    		$-0.77$-0.84+8.33%Beat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.17
    SMA 20$3.16
    SMA 50$3.12
    SMA 200$3.06
    EMA 10$3.17
    EMA 20$3.16
    EMA 50$3.06
    EMA 200$2.83

    MACD

    Line: 0.03Signal: 0.04Hist: -0.01

    ADX

    ADX: 35.8+DI: 24.1-DI: 11.4

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down52.0
    PSAR$3.11

    Bollinger Bands

    Upper Band$3.19
    Lower Band$3.14
    %B Position169%(Upper)
    Band Width0.83

    RSI (14-Day)

    Neutral
    64.8

    Momentum Oscillators

    Stoch %K88.9
    Stoch %D91.7
    Williams %R-16.7
    ROC (10d)0.3%
    Momentum0.01
    CCI (20d)147.4
    MFI (14d)88.1

    Volatility Measures

    ATR (14d)$0.02(0.7%)
    StdDev (20d)0.01
    Hist Vol6.2%(Low)

    Volume Flow

    VWAP$3.18
    OBV244.5M
    AD Line-64.8M
    CMF (20d)0.110

    Volume Metrics

    Avg Vol (20d)15.7M
    Vol RatioN/A
    VWMA (20d)$3.17

    Pivot Points

    R3$3.20
    R2$3.19
    R1$3.19
    Pivot Point$3.18
    S1$3.18
    S2$3.17
    S3$3.17

    Advanced Oscillators

    TSI32.74
    Ultimate Osc53.4
    KST9.03

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$80.10M$168.45M$87.31M$82.39M$65.00M$69.11M$51.63M$73.83M$137.74M$32.25M$33.97M$25.79M
    Cost of Revenue$0$129.22M$0$0$0$68.60M$0$0$0$43.27M$0$0
    Gross Profit$80.10M$39.22M$87.31M$82.39M$65.00M$512,000$51.63M$73.83M$137.74M$-11,017,000$33.97M$25.79M
    Operating Expenses$86.69M$-46,011,000$97.27M$75.29M$87.09M$4.93M$67.66M$71.25M$65.47M$31.35M$61.50M$62.84M
    R&D$8.99M$13.93M$14.13M$7.24M$12.56M$10.98M$10.40M$11.46M$13.40M$17.74M$14.88M$22.10M
    SG&A$77.70M$-59,937,000$83.14M$68.05M$74.53M$-6,045,000$57.26M$59.79M$52.06M$13.61M$46.62M$40.74M
    Operating Income$-6,581,000$85.23M$-9,959,000$7.09M$-22,096,000$-4,420,000$-16,026,000$2.58M$72.27M$-42,367,000$-27,533,000$-37,058,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$19.80M$22.64M$22.05M$20.49M$19.43M$18.11M$15.08M$66.96M$14.02M$15.06M$14.99M$14.54M
    Income Before Tax$-26,379,000$66.09M$-32,010,000$-13,391,000$-41,527,000$-16,087,000$-29,524,000$-64,379,000$58.24M$-53,406,000$-42,528,000$-51,595,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-25,196,000$61.83M$-31,333,000$-12,725,000$-40,455,000$-21,318,000$-29,524,000$-61,925,000$61.02M$-56,344,000$-41,250,000$-49,935,000
    EBITDA$-5,965,000$85.90M$-9,086,000$7.94M$-21,371,000$-4,221,000$-13,969,000$3.03M$72.71M$-41,930,000$-27,080,000$-36,658,000
    EBIT$-6,581,000$85.23M$-9,959,000$7.09M$-22,096,000$-4,420,000$-14,442,000$2.58M$72.27M$-42,367,000$-27,533,000$-37,058,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ESPR

    News

    Esperion Therapeutics, Inc. Revenue Breakdown – LS:A1W1SJ

    Esperion Therapeutics, Inc. (A1W1SJ) reported total revenue of €343.24 million last year, primarily from its "Patients with Elevated Low-density Lipoprotein Cholesterol" segment. The United States was the company's largest contributor to revenue, generating €343.24 million in the last fiscal year. This marks an increase from the previous year's total revenue of €321.01 million.

    TradingView•8/1/26•
    Neutral

    Vanguard Capital Management (ESPR) reports 13.1M-share, 5.08% stake in Esperion

    Vanguard Capital Management has reported a 5.08% stake in Esperion Therapeutics Inc. (ESPR), amounting to 13,105,104 shares. The filing indicates Vanguard has sole voting power over 1,677,667 shares and sole dispositive power over all 13,105,104 shares, with no shared control. This position is held across various Vanguard investment companies and managed accounts, and no single person's interest within this holding exceeds 5%.

    Stock Titan•7/31/26•
    Neutral

    Esperion Therapeutics Inc (ESPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

    This article from TradingKey provides a revenue breakdown for Esperion Therapeutics Inc (ESPR). It states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The article includes current stock information for ESPR.

    TradingKey•7/28/26•
    Neutral

    Esperion Therapeutics Inc (ESPR) Dividends & Stock Splits: Historical Payouts and Event Timeline

    The article provides an overview of Esperion Therapeutics Inc (ESPR) focusing on its dividends and stock splits. It states that no dividends have been distributed over the past five years. The current stock price is $3.180, and the company has an 819.46M Market Cap.

    TradingKey•7/27/26•
    Neutral

    Esperion Therapeutics Inc (ESPR) Cash Flow

    This article provides a detailed cash flow statement for Esperion Therapeutics Inc (ESPR), showing quarterly and annual data for operating, investing, and financing activities. It includes definitions for various cash flow metrics and highlights the company's operating cash flow for fiscal 2025 at -13.09M, marking a 44.65% increase year-over-year. The free cash flow for the latest quarter was also -13.09M, reflecting a 45.38% change from the previous year.

    TradingKey•7/26/26•
    Neutral

    Frequently Asked Questions About ESPR

    Does ESPR pay dividends?
    ESPR (ESPR) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In